Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients
Sophie Périnel, Manon Launay, Élisabeth Botelho-Nevers, Éric Diconne, Aurore Louf-Durier, Raphaël Lachand, Martin Murgier, Dominique Page, Régine Vermesch, Guillaume Thierry, Xavier Delavenne
Abstract
Hydroxychloroquine (HCQ) appears to be a promising treatment for COVID-19. However, all ongoing clinical trials with HCQ use different dosing regimens, resulting in various concentrations. Pharmacokinetic studies are therefore needed to define the optimal dosing regimen.
Topics & Concepts
HydroxychloroquineDosingMedicineCoronavirus disease 2019 (COVID-19)PharmacokineticsIntensive care medicine2019-20 coronavirus outbreakIntensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)RegimenClinical trialPandemicPharmacologyInternal medicineVirologyInfectious disease (medical specialty)DiseaseOutbreakAntibiotics Pharmacokinetics and EfficacyPharmacological Receptor Mechanisms and EffectsDrug-Induced Ocular Toxicity